menu
    • menu
    [{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verismo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2023","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verismo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verismo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"SynKIR-110","moa":"T-cell receptor","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verismo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2022","type":"Inapplicable","leadProduct":"Autologous T Cell Transduced With Mesothelin KIR-CAR","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verismo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SynKIR-310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verismo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"SynKIR-310","moa":"Undisclosed","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Verismo Therapeutics \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Undisclosed"},{"orgOrder":0,"company":"Verismo Therapeutics","sponsor":"Miltenyi Biotec","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Cell & Gene Therapy","year":"2025","type":"Collaboration","leadProduct":"SynKIR-110","moa":"MSLN","graph1":"Oncology","graph2":"Phase I","graph3":"Verismo Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Verismo Therapeutics \/ Verismo Therapeutics","highestDevelopmentStatusID":"6","companyTruncated":"Verismo Therapeutics \/ Verismo Therapeutics"}]

    Find Clinical Drug Pipeline Developments & Deals by Verismo Therapeutics

    Menu

    Verismo Therapeutics

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Recipient : Miltenyi Biotec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Verismo Therapeutics Partners Miltenyi Biotec for Clinical Program Support

                            Details : The collaboration aims to advance SynKIR-110 gene therapy targeting Mesothelin for solid tumors.

                            Product Name : SynKIR-110

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            September 25, 2025

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Recipient : Miltenyi Biotec

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SynKIR-310

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verismo Activates CELESTIAL-301 Trial at Colorado Blood Cancer Institute

                            Details : SynKIR-310 targets a similar epitope of CD19 as the commercially approved CAR T therapies. It is being evaluated for treating r/r B-cell Non-Hodgkin Lymphomas.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 08, 2024

                            Lead Product(s) : SynKIR-310

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SynKIR-310

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SynKIR-310 for Relapsed/Refractory B-NHL

                            Details : SynKIR-310 is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Lymphoma, B-Cell.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 09, 2024

                            Lead Product(s) : SynKIR-310

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verismo Therapeutics Announces the Activation of its STAR-101 Clinical Trial at the University of Pennsylvania

                            Details : SynKIR™-110 is a CAR T cell therapy (T cell inducer) that uses a novel KIR-CAR platform technology to transform the treatment of mesothelin-overexpressing malignant pleural mesothelioma, cholangiocarcinoma and ovarian cancer.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 02, 2023

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verismo Therapeutics Secures Fast Track Designation from the U.S. Food and Drug Administration (FDA) for SynKI...

                            Details : SynKIR-110 is an investigational new drug for the treatment of mesothelin-expressing mesothelioma, cholangiocarcinoma and ovarian cancer. Verismo Therapeutics is conducting a Phase 1 clinical trial to evaluate the safety, feasibility and anti-tumor activ...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 05, 2023

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Autologous T Cell Transduced With Mesothelin KIR-CAR

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma

                            Details : Autologous T Cell Transduced With Mesothelin KIR-CAR is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Ovarian Neoplasms.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            October 06, 2022

                            Lead Product(s) : Autologous T Cell Transduced With Mesothelin KIR-CAR

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verismo Therapeutics Announces FDA Clearance of IND Application for SynKIR-110™, a KIR-CAR T Cell Immunother...

                            Details : The Phase 1 trial, STAR-101, will assess safety, tolerability, and preliminary efficacy of SynKIR-110 in patients with mesothelin expressing ovarian cancer, cholangiocarcinoma and mesothelioma. This first-in-human trial seeks to address several areas of ...

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            September 20, 2022

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Verismo Therapeutics

                            U.S.A arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Verismo Therapeutics Seeks US FDA Approval to Begin Phase 1 trial of SynKIR-110 in Patients With Mesothelin-Ex...

                            Details : Company advances towards in-human clinical trials for SynKIR-110 platform targeting Mesothelin-Expressing Advanced Ovarian Cancer, Cholangiocarcinoma, and Mesothelioma.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            August 22, 2022

                            Lead Product(s) : SynKIR-110

                            Therapeutic Area : Oncology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth